Portal de Periódicos da CAPES

Type 2 Diabetes and ADP Receptor Blocker Therapy

2015; Hindawi Publishing Corporation; Volume: 2016; Linguagem: Inglês

10.1155/2016/6760710

2314-6753

Matej Samoš, Marián Fedor, František Kovář, Michal Mokáň, Tomáš Bolek, Péter Galajda, Peter Kubisz, Marián Mokáň,

Venous Thromboembolism Diagnosis and Management

Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy.